Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
Myelodysplastic syndromes are a heterogeneous group of diseases with variable outcomes. To refine the original IPSS, international MDS databases were combined for analysis (yielding a total population of n=7012). Modeling of prognostic risk was based on multivariate analysis of survival time and time to AML transformation.
Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the revised IPSS, but with refinement of the category thresholds and addition of age, performance status, serum ferritin, and LDH.
References
The original IPSS was proposed and validated by revised/developed by
Greenberg et al.
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes.
Blood 1997;89:2079-2088
The revised model was developed by
Greenberg et al.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes.
Blood 2012;120(12):2454-2465).
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]